United StatesÚltimas notícias

UIS initial jobless claims decreased by 2,000 to 215,000 in the week ended July 4, a period that included the Independence Day holiday. The median forecast in a Bloomberg survey of economists called for 217,000 applications. Mike McKee reports on "Bloomberg Open Interest."

TOMI Environmental Solutions (NASDAQ:TOMZ) reported a 124% year-over-year increase in preliminary second-quarter revenue to $2.3 million.

Teva (NYSE:TEVA) signed a global licensing agreement with Polpharma Biologics for a proposed multiple sclerosis biosimilar.

Steel Partners Holdings offered to acquire all outstanding shares of InMode (NASDAQ:INMD) for $16.75 each.

Meta Platforms (NASDAQ:META) will begin manufacturing its in-house Iris artificial intelligence processor in September.

Seven Hills Realty Trust (NASDAQ:SEVN) announced a regular quarterly cash distribution of $0.28 per common share.

Delcath Systems (NASDAQ:DCTH) dosed the first patient in a 90-person Phase 2 clinical trial evaluating a cancer therapy.

Northern Technologies (NASDAQ:NTIC) reported third-quarter fiscal 2026 sales of $24.2 million.

Byrna Technologies (NASDAQ:BYRN) reported a steep contraction in its financial metrics for the second quarter of 2026, navigating a heavy product restructuring phase marked by deep asset write-downs and an overhaul of its manufacturing footprint.

Andrew Graham, Jackson Square Capital Founder and Portfolio Manager, joins Bloomberg's Vonnie Quinn on "Bloomberg Brief" to discuss the rebound in equities.

PepsiCo (NASDAQ:PEP) delivered a dependable set of operational results for the second quarter of 2026, driven by a sharp rebound in underlying sales volumes across its international portfolios and an evolving product mix.

CervoMed (NASDAQ:CRVO), a clinical-stage biotechnology company focused on treating age-related brain disorders, announced today that it has finalized patient enrollment for its Phase 2a clinical trial evaluating its lead drug candidate, neflamapimod, in individuals with nonfluent variant primary progressive aphasia (nfvPPA).